Contineum Therapeutics, INC Form 4 insider transactions

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock for a weighted average price of $12.2324 per share.

Contineum Therapeutics, Inc. Director Sarah Boyce was granted 14,750 stock options with an exercise price of $4.01 per share, as part of the company's non-employee director compensation program.

Contineum Therapeutics, Inc. Director Evert B. Schimmelpennink was granted 14,750 stock options with an exercise price of $4.01, vesting over one year or until the next annual meeting.

Contineum Therapeutics, Inc. Director Todd R. Brady was granted 14,750 stock options as part of the company's non-employee director compensation program.

Contineum Therapeutics, Inc. Director Troy A. Ignelzi was granted 14,750 stock options at an exercise price of $4.01 as part of the company's non-employee director compensation program.

Contineum Therapeutics, Inc. Director Lori Lyons-Williams was granted 14,750 stock options as part of the company's non-employee director compensation program.

Contineum Therapeutics, Inc. Director Olivia Ware was granted 14,750 stock options at an exercise price of $4.01, vesting over one year or until the next annual meeting, as part of the company's non-employee director compensation program.

Contineum Therapeutics, Inc. Director Miralles Gines Diego was granted 14,750 stock options as part of the company's non-employee director compensation program.

Tim Watkins, CMO & Head of Development at Contineum Therapeutics, received stock options as an inducement grant outside of the company's equity incentive plan.

Director Miralles Gines Diego reports the acquisition of stock options in Contineum Therapeutics, Inc.

John Stephen Healy, General Counsel and Corporate Secretary of Contineum Therapeutics, acquired stock options for 63,589 shares on January 31, 2025.

Contineum Therapeutics' Chief Financial Officer, Peter Slover, was granted 110,000 stock options under the company's 2024 Equity Incentive Plan.

Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, reports the acquisition of stock options.

Stephen L. Huhn, CMO & Sr VP, Clinical Development at Contineum Therapeutics, was granted stock options for 110,000 shares on January 31, 2025.

Contineum Therapeutics CEO Carmine N. Stengone was granted 300,000 stock options on January 31, 2025, under the company's 2024 Equity Incentive Plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,010 shares of Class A Common Stock at an average price of $16.0172, as part of a pre-arranged 10b5-1 trading plan.

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 6,190 shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Stephen L. Huhn, CMO & Sr VP, Clinical Development at Contineum Therapeutics, exercised stock options to acquire 12,800 shares of Class A Common Stock at $1.01 per share.

Director Sarah Boyce acquired stock options in Contineum Therapeutics, Inc. on June 24, 2024.

John Stephen Healy, General Counsel and Corporate Secretary of Contineum Therapeutics, was granted stock options for 160,000 shares on June 3, 2024.

Contineum Therapeutics CEO Carmine N. Stengone was granted 285,000 stock options under the company's 2024 Equity Incentive Plan.

Contineum Therapeutics' Chief Financial Officer, Peter Slover, was granted 100,000 stock options on May 24, 2024, under the company's 2024 Equity Incentive Plan.

Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, was granted stock options for 103,700 shares of Class A Common Stock on May 24, 2024.

Stephen L. Huhn, CMO & Sr VP, Clinical Development at Contineum Therapeutics, Inc., was granted stock options to purchase 100,000 shares of Class A Common Stock on May 24, 2024.

Director Troy A. Ignelzi receives stock options from Contineum Therapeutics under the 2024 Equity Incentive Plan.

Director Olivia C. Ware receives 3,700 stock options from Contineum Therapeutics under the 2024 Equity Incentive Plan.

Director Lori Lyons-Williams received 29,500 stock options in Contineum Therapeutics, Inc. on May 24, 2024, under the company's 2024 Equity Incentive Plan.

Director Todd R. Brady receives 29,500 stock options in Contineum Therapeutics under the company's 2024 Equity Incentive Plan.

Director Evert B. Schimmelpennink received stock options for 29,500 shares of Contineum Therapeutics, Inc. (CTNM) on May 24, 2024, as part of the company's Non-Employee Director Compensation Program.

Director Troy A. Ignelzi reports the acquisition of stock options in Contineum Therapeutics, Inc.